Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Kaur H, Samarska I, Lu J, Faisal F, Maughan BL, Murali S, et al. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance. Prostate. 2020;80(12):1012-1023.

Vosoughi A, Zhang T, Shohdy KS, Vlachostergios PJ, Wilkes DC, Bhinder B, et al. Common germline-somatic variant interactions in advanced urothelial cancer. Nat Commun. 2020;11(1):6195.

Basourakos SP, Kasabwala K, Silich R, Mosquera JM, Choi B. Neurofibroma originating from a urachal mass. Can J Urol. 2020;27(5):10407-10410.

Lopez A, Trager MH, Magro C, Geskin LJ. Collisional variant of CD8 mycosis fungoides and indolent CD8 lymphoid proliferation. JAAD Case Rep. 2020;6(9):921-924.

Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, et al. Correction: Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. Leukemia. 2020;34(11):3105.

Goel S, Shoag JE, Gross MD, Awamlh BA, Robinson B, Khani F, et al. Concordance Between Biopsy and Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2020;3(1):10-20.

Casiraghi N, Orlando F, Ciani Y, Xiang J, Sboner A, Elemento O, et al. ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA. Bioinformatics. 2020;36(9):2665-2674.

Wang Q, Jia S, Wang D, Chen X, Kalvakolanu DV, Zheng H, et al. A Combination of BRD4 and HDAC3 Inhibitors Synergistically Suppresses Glioma Stem Cell Growth by Blocking GLI1/IL6/STAT3 Signaling Axis. Mol Cancer Ther. 2020;19(12):2542-2553.

Chung EY, McIlroy K, Fung C, Seshan SV, Moran S, Coleman PL. Glomerular, Mesangial, and Tubular Cytoplasmic Fibrillary Inclusions in a Patient with Light-Chain Proximal Tubulopathy. Nephron. 2020;144(4):190-194.

Cheleuitte-Nieves C, Heselpoth RD, Westblade LF, Lipman NS, Fischetti VA. Searching for a Bacteriophage Lysin to Treat in Immunocompromised Mice. Comp Med. 2020;70(4):328-335.